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Abstract
Breast cancer remains the second leading
cause of cancer death among women in the
United States, with 99% of breast cancer
patients surviving five years after diagnosis if
the tumor is localized. However, if the tumor
has metastasized, the survival rate decreases to
22%. Epidemiological and animal studies, as
well as previous studies from our laboratory
in in vitro 3D cell culture models, support
the hypothesis that vitamin D may inhibit
breast cancer metastasis in humans, but the
mechanisms remain unknown. The purpose
of the present studies was to investigate the
effect of the bioactive vitamin D metabolite,
1α,25-dihydroxyvitamin D3 (1,25(OH)2D) on
expression of matrix metalloproteinases
(MMP) in MCF10CA1a breast epithelial cells.
MMPs are a family of endopeptidases implicated
in both cancer cell invasion and migration. First,
the pattern of MMP expression in MCF10CA1a
cells was investigated, focusing on MMPs 1,2,3,9
and 13. MCF10CA1a cells expressed only
MMP2 mRNA at a detectable level. Treatment
with 1,25(OH)2D (10 nM,) reduced the expression of MMP2 by 32%±10 and 35%±7 at 2
and 5 days, respectively. Furthermore, the
effect of 1,25(OH)2D on migratory capability
of MCF10CA1a cells was assessed using
a wound healing assay. Pretreatment with
1,25(OH)2D for 48 hours decreased cell migration by 44%±9.6 relative to vehicle. Overall,
these studies support a potential role of MMP2
and migration in 1,25(OH)2D prevention of
breast cancer metastasis.
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Breast cancer remains the second leading cause of
cancer death and is the most frequently diagnosed
cancer among women, with an expected 40,610
deaths due to breast cancer and 252,710 new cases
to be diagnosed in 2017 (American Cancer Society,
2017). The survival rate of breast cancer patients is
high, with 99% of patients surviving if the tumor is
localized. However, if the tumor has metastasized,
the survival rate decreases to 22% depending on the
diagnosed stage (American Cancer Society, 2015;
Yücel, et al., 2014). In addition, studies also show
70% of patients who are diagnosed with metastatic
breast cancer at an advanced stage develop bone
metastasis (Ahn et.al., 2013).
Cancer cells must break down physical barriers,
including the extracellular matrix and basement membrane, in order for cancer cells to escape the primary
tumor to a secondary site (thus metastasizing), which
requires the expression of matrix metalloproteinases
(MMPs). MMPs are zinc-dependent extracellular
matrix (ECM) remodeling endopeptidases, which
have the ability to degrade most components of the
ECM. There are 26 known MMPs that are highly
homologous yet differ in their substrate specificities.
Each enzyme has a signal peptide to direct trafficking
through the secretory pathway and a well-conserved,
compact, catalytic domain (Radisky & Radisky,
2015). Studies show that MMPs are able to modulate
the tumor microenvironment and regulate signaling
pathways that control cell growth and migration, the
immune system, and angiogenesis (Kessenbrock,
2010). Imbalances in the activity of MMPs can activate cellular processes that cause DNA damage and
stimulate genomic instability (Wilmanski, Buhman,
Donkin, Burgess, & Teegarden, 2017). MMPs may
also directly induce phenotypic changes associated
with the epithelial-mesenchymal transition, a developmental process that becomes activated during tumor
progression (Wilmanski et al., 2017). MMPs could
stimulate resistance to chemotherapeutics and drive
tumor progression through proteolytic inactivation of
the cell death receptor Fas and consequent inhibition
of the intrinsic apoptosis pathway. Furthermore,
findings suggest MMP overexpression may indicate
a higher risk of poor prognosis in breast cancer
(Ren et al., 2015).
Evidence suggests that vitamin D may protect
against breast cancer as well as breast cancer
metastasis. Vitamin D can be obtained through sun
exposure, food, and supplements; however, vitamin
D deficiency is prevalent in the United States The
Teegarden laboratory has previously demonstrated
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INTRODUCTION

the effect of the active form of vitamin D,
1,25-dihydroxyvitamin D (1,25(OH)2D) on inhibiting
metastasis of breast cancer cells in an in vitro model
of the breast to bone metastasis (rMET) (Wilmanski
et al., 2016). However, the molecular mechanisms for
1,25(OH)2D-mediated inhibition of metastasis are
unknown. Therefore, further studies are needed to
investigate the effect and mechanisms through which
vitamin D inhibits breast cancer metastasis.
MMP activity is important to the first steps of metastasis to evade the primary site; however, the role of
MMPs in 1,25(OH)2D-mediated inhibition of metastasis is unknown. Thus, the focus of this project is
to investigate the role of 1,25(OH)2D in altering the
mRNA expression of MMPs to inhibit the invasion
and migration of breast cancer cells.

MMP1
Forward Primer

AGCGTGTGACAGTAAGCTAAC

Reverse Primer

TCCTCAGAAAGAGCAGCATCG

MMP2		
Forward Primer

AGATGCCTGGAATGCCAT

Reverse Primer

GGTTCTCCAGCTTCAGGTAAT

MMP3
Forward Primer

GACAAAGGATACAACAGGGACCA

Reverse Primer

ACCGAGTCAGGTCTGTGAGT

MMP9
Forward Primer

CAACATCACCTATTGGATCC

Reverse Primer

CGGGTGTAGAGTCTCTCGCT

METHODS
Cell Culture

MMP13
Forward Primer

TGTAAAACGACGGCCAGT

In this study, MCF10CA1a cells were utilized. These
cells are mammary epithelial cells that represent
the metastatic stage of cancer progression with the
potential to invade distant secondary organs. MCF10CA1a cells were given as a gift from Dr. Julia
Kirshner (Purdue University). For these experiments,
cells were cultured in DMEM/F12, 1:1 supplemented
with 5% horse serum, 100-units/ml Penicillin, and
100-ug/mL streptomycin. Cells were treated with
vehicle (ethanol) or 1,25(OH)2D (10 nm) (BIOMOL
International) and delivered in 100% ethanol with a
final ethanol concentration of <1%.The media was
changed every 24 hours for the treatment period
(Wilmanski et al., 2017).

Reverse Primer

CAGGAAACAGCTATGACC

Scratch Wound Healing Assay
MCF10CA1a cells were plated in 6 well plates with
90% confluence and scratched with a 200 ul pipette
tip. After 48 hours, the MCF10CA1a cells were
treated with vehicle or 1,25(OH)2D (10 nM). The new
media containing 0.5% serum was added containing
vehicle of 1,25(OH)2D, and images of wound closure
were taken at time 0 and 24 hours. The results were
quantified through TScratch.

Real-Time Quantitative PCR
RNA was isolated with TriReagent. Reverse transcription of total RNA was performed using MMLV
reverse transcriptase, and real-time quantitative PCR
was performed using the Brilliant II SYBR Green
QPCR Master Mix. The mRNA expression was normalized to 18S expression (Wilmanski et al., 2017).
The primers used are shown in Table 1.
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Table 1. Primer sequences for MMPs.

RESULTS
MMPs have been implicated in the processing of
cytokines, growth factors, and cell adhesion molecules, demonstrating their importance in sustaining
a cancer cell’s migratory potential. There is also
evidence that supports MMPs having a role in tumor
progression and metastasis, in shaping the tumor
microenvironment, and in driving cancer progression
and metastasis (Radisky & Radisky, 2015).
In order to study the impact of the active form of
vitamin D, 1,25(OH)2D, on breast to bone metastasis, a unique 3-D cell model that recapitulates the
transition steps that occur during breast cancer cell
metastasis to the bone was utilized (Parikh, Belch,
Pilarski, & Kirshner, 2014; Parikh, Minser, Rank,
Glackin, & Kirshner, 2014). In this model system,
the metastatic cells are plated in matrigel in an upper
transwell, and the transwell is inserted into a well,
which contains on the bottom a coating that is similar
to a bone environment. The cells were treated only
in the upper well with 1,25(OH)2D, and the number
of viable cells that implant and grow in the bone matrix was assessed. Using this model, experiments in
our laboratory showed that the number of viable metastatic MCF10CA1a breast cells that successfully metastasized to the bone matrix is drastically decreased
by 70% with 1,25(OH)2D treatment (Wilmanski et
al., 2016). In addition, similar results were obtained
with the metastatic MDA-MB-231 breast cancer cell

line, with a 20% reduction in cell viability in the
lower bone matrix. It is noteworthy to emphasize that
there was no 1,25(OH)2D in the bone cell conditioned
media, and thus, the altered phenotype and survival
are due to the treatment in the upper well prior to
movement into the bottom well. Therefore, the effects on metastasis to the bone are due, at least in
part, to the treatment of the cells prior to and during
invasion and migration from the upper well.

Impact of 1,25(OH)2D on
Migration of MCF10CA1a
The role of 1,25(OH)2D in the migration or movement
of metastatic cells (MCF10CA1a cells) is important
to understand in order to determine how metastasis
is inhibited. Therefore, due to the important role of
migration in metastasis, the effect of 1,25(OH)2D on
migration of MCF10CA1a cells was examined by a
wound healing assay. As shown in Figure 1, pretreatment of cells with 1,25(OH)2D for 48 hours decreased
cell migration by 44%±9.6 relative to vehicle. The
respective images can be seen in Figure 2.

Impact of 1,25(OH)2D on MMP mRNA Expression

Figure 1. 1,25(OH)2D inhibits migration of MCF10CA1a
cells. MCF10CA1a cells were treated with vehicle or
1,25(OH)2D (10nM) for 48 hours, after which each well
was scratched with a 200ul pipette tip. New media
containing 0.5% serum was added containing vehicle
or 1,25(OH)2D, and wound closure was monitored for 40
hours. *Indicates p-value < 0.05 relative to vehicle.
0h

24h

1,25(0h)2D
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The impact of 1,25(OH)2D treatment on the mRNA
abundance of a variety of MMPs was investigated
through real-time quantitative PCR. MMP1, MMP3,
MMP9, and MMP13 mRNA levels were undetectable in MCF10CA1a cells. However, MMP2 mRNA
expression levels were detectable. MMP2 mRNA
abundance was significantly downregulated after
48 hours and 5 days of 1,25(OH)2D treatment. Treatment with 1,25(OH)2D (10 nM) reduced the expression of MMP2 by 32% ± 10 and 35% ± 7  at 2 and 5
days, respectively, as seen in Figure 3.

Figure 3. 1,25(OH)2D decreases mRNA expression
of MMP2 in MCF10CA1a cells. MCF10CA1a cells were
treated with vehicle or 1,25(OH)2D (10nM) for 48
hours and 5 days, after which mRNA was isolated and
expression was quantified using qRT-PCR. *Indicates
p-value < 0.05 relative to vehicle.
Figure 2. Representative images of MCF10CA1a breast
epithelial cells from wound healing assay.
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DISCUSSION
Epidemiological and animal studies support the
hypothesis that vitamin D may inhibit breast cancer
metastasis in humans, but the mechanism remains
unknown. There are a number of studies in humans
that show that vitamin D status is associated
with reduced risk for metastasis including breast
cancer (Ren et al., 2012; Hauser, Walsh, Shrotriya,
& Karafa, 2014; Neuhouser et al., 2008; Mohr,
Gorham, Kim, Hofflich, & Garland, 2014). Further,
perfusion with the circulating metabolite of
vitamin D, 25-hydroxyvitamin D (25(OH)D), in an
MMTV-PyMT mouse model of metastatic breast
cancer increased levels of the bioactive vitamin D
metabolite, 1,25(OH)2D in the tumor, showing that
increasing vitamin D status increases the local level
of the active form of the vitamin in the tissue, In
addition, tumor appearance was delayed, and lung
metastasis decreased in this study (Rossdeutscher
et al., 2014). In addition to studies in vivo, studies
in cell models also support the hypothesis that
1,25(OH)2D or its analogues inhibit metastasis,
including invasion through matrigel and migration
of MCF-7 and MCF10DCIS cells, and changes
in expression of markers of metastatic capability.
Therefore, evidence exist that 1,25(OH)2D inhibits
invasive and migratory capability of breast cancer
cells in vitro and the metastasis of breast cancer
cells in vivo. Despite illustrating this beneficial
effect, the mechanistic basis for the inhibitory
action of vitamin D on breast cancer metastasis
remains poorly understood. It is critical to
understand this mechanism to appropriately design
clinical trials with well-defined and measurable
outcomes, and to determine when and to whom
interventions should be targeted.
Previous studies have shown the matrix metalloproteinase family to have a role in cancer and tumor
metastasis. Of the 26 MMPs, MMP1, 2, 7, 9, 11, 13,
and 14, along with the tissue inhibitors of MMPs,
were quantified in invasive ducal breast tumors.
MMP2 and MMP9 also have been examined as
prognostic biomarkers in breast cancer (Radisky
& Radisky, 2015). Thus, one mechanism by which
1,25(OH)2D may inhibit metastasis is through downregulation of the expression of MMPs; however, this
has not been examined.
The results of the current study demonstrate that
1,25(OH)2D can downregulate the mRNA levels of
MMP2, which may lead to a potential change in the
protein expression. Therefore, vitamin D through its
active form, 1,25(OH)2D, may be an effective agent
in inhibiting invasion of breast cancer cells through
6

Journal of Purdue Undergradate Research: Volume 7, Fall 2017

downregulating MMP2 expression. In addition, the
downregulation of MMP2 may play a role in inhibiting the migration of metastatic breast cancer cells.
Vitamin D is a food component and is synthesized by
human bodies. Thus, it is a safe component to recommend for preventing metastasis. If the mechanisms
of how vitamin D inhibits metastasis are determined,
strategies can be developed to recommend specific
intakes of the vitamin and may be targeted to specific
populations to reduce the development of metastasis. Since breast cancer metastasis greatly reduces
the survivability of the cancer, the impact of these
studies, when translated to the clinic and general
population, may have a significant impact to reduce
mortality associated with breast cancer.

FURTHER STUDIES
Our preliminary studies have shown that 1,25(OH)2D
inhibits the migratory capability of MCF10CA1a
cells using a wound healing assay. To further explore
the impact of 1,25(OH)2D, additional wound healing
assays with other cell lines such as the MDA-MB-231
and 4T1 are necessary to ensure the effect is not
specific to one cell line.
In addition, it is important to determine if the
downregulation of MMP2 by 1,25(OH)2D treatment
plays a role in the inhibition of migration. To test
this, inhibitors or activators of MMP2 activity can
be used in the presence of vehicle or 1,25(OH)2D and
migration assessed. In particular, MMP2 targeting
siRNA to knockdown MMP2 expression or overexpression of MMP2 in metastatic breast epithelial
cells can be utilized. The MMP2 knockdown is
expected to significantly inhibit both migration and
invasion of metastatic breast epithelial cells, with
1,25(OH)2D having no further effect on cell invasion.
Similarly, we expect that a constitutive increase in
MMP2 activity will significantly reduce or eliminate
the 1,25(OH)2D inhibition of migration of metastatic
breast epithelial cells.
Because of the important role of MMP2 in invasion,
the impact of 1,25(OH)2D on invasive capability in the
same breast epithelial metastatic cells (MCF10CA1a,
MDA MB 231, and 4T1) also can be investigated. The
invasion assay utilizes FluoroBlok matrigel coated
transwell inserts with 8µm pore membrane. This cell
culture system allows for quick invasive cell quantification using Calcein AM and subsequent fluorescence
quantification. Fluorescently labeled cells present
in the top chamber of the insert are shielded from
bottom-reading fluorescence plate readers and microscopes by the FluoroBlok membrane.
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